🇺🇸 FDA
Patent

US 8765125

Methods of treating autoimmune diseases with Dll4 antagonists

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 8765125 (Methods of treating autoimmune diseases with Dll4 antagonists) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P